Abionic SA
Abionic SA specializes in rapid diagnostic solutions that integrate seamlessly into clinical workflows, providing lab-quality results from a drop of blood within minutes. Their mission is to improve patient outcomes and support healthcare professionals worldwide through innovative, near-patient testing platforms and biomarkers, particularly for early sepsis detection and other critical care applications.
Industries
Nr. of Employees
medium (51-250)
Abionic SA
Patents
Capsule for rapid molecular quantification of a fluid sample such as whole blood
US-10434508-B2
View DetailsRapid quantification of biomolecules in a selectively functionalized nanofluidic biosensor and method thereof
US-9547004-B2
View Details
Capsule for rapid molecular quantification of a fluid sample such as whole blood
US-10434508-B2
View DetailsRapid quantification of biomolecules in a selectively functionalized nanofluidic biosensor and method thereof
US-9547004-B2
View DetailsProducts
Nanofluidics-based near-patient diagnostic platform
A near-patient diagnostic platform that implements nanofluidics-based assays to produce lab-quality biomarker results from a small volume of blood within minutes; intended to support rapid clinical decision-making for time-sensitive conditions such as sepsis.
Nanofluidics-based near-patient diagnostic platform
A near-patient diagnostic platform that implements nanofluidics-based assays to produce lab-quality biomarker results from a small volume of blood within minutes; intended to support rapid clinical decision-making for time-sensitive conditions such as sepsis.
Services
Support and/or execution of prospective cohorts, multicenter studies, systematic reviews and pooled analyses to evaluate biomarker diagnostic and prognostic performance.
Integration services for near-patient diagnostic solutions into triage, critical care monitoring and ward workflows, including connectivity to HIS/LIS and configuration for local clinical pathways.
Clinical education and dissemination activities including webinars, conference presentations and expert-led sessions on biomarker utility and sepsis screening protocols.
Support and/or execution of prospective cohorts, multicenter studies, systematic reviews and pooled analyses to evaluate biomarker diagnostic and prognostic performance.
Integration services for near-patient diagnostic solutions into triage, critical care monitoring and ward workflows, including connectivity to HIS/LIS and configuration for local clinical pathways.
Clinical education and dissemination activities including webinars, conference presentations and expert-led sessions on biomarker utility and sepsis screening protocols.
Expertise Areas
- Early sepsis detection and screening
- Point-of-care diagnostics and near-patient testing
- Biomarker development and clinical validation
- Clinical evidence generation and meta-analysis
Key Technologies
- Nanofluidics-based assay technology
- Point-of-care immunoassay methods
- Capillary (single-drop) blood sampling
- Enzyme-linked immunosorbent assay (ELISA)
News & Updates
Abionic will attend the 'Sepsis – Today and Tomorrow' session at ISICEM in Rome, from December 15 to 18, 2024.
The CEO will be in San Francisco during the JPMorgan Healthcare Conference from January 13-17, 2025, to discuss early sepsis detection solutions.
Participation in the ABA Annual Meeting in Phoenix, AZ, from April 8-11, 2025, focusing on sepsis biomarkers in burn care.
A review article discussing the role of PSP in sepsis diagnosis and management, highlighting its utility as a biomarker.
A study evaluating the diagnostic and prognostic value of PSP in patients with suspected sepsis, showing its utility in early detection and outcome prediction.
Research demonstrating PSP's ability to predict mortality in septic ICU patients, supporting its use for risk stratification.
Abionic will attend the 'Sepsis – Today and Tomorrow' session at ISICEM in Rome, from December 15 to 18, 2024.
The CEO will be in San Francisco during the JPMorgan Healthcare Conference from January 13-17, 2025, to discuss early sepsis detection solutions.
Participation in the ABA Annual Meeting in Phoenix, AZ, from April 8-11, 2025, focusing on sepsis biomarkers in burn care.
A review article discussing the role of PSP in sepsis diagnosis and management, highlighting its utility as a biomarker.
A study evaluating the diagnostic and prognostic value of PSP in patients with suspected sepsis, showing its utility in early detection and outcome prediction.
Research demonstrating PSP's ability to predict mortality in septic ICU patients, supporting its use for risk stratification.